Sensorion: Sensorion Announces Preclinical Data Demonstrating SENS-401's Potential to Preserve Residual Hearing After Cochlear Implantation
Statistically significant protective effect at a frequency located beyond the electrode array at 8 months post implantation Statistically significant electrode impedance reduction observed with SE...
Read full article »
Sensorion is a biopharmaceutical company that develops and commercializes novel therapies for the treatment of inner ear diseases.
Read more